Vivid Dx Raises $15M Seed Funding to Advance AI-Powered Rapid Diagnostics for Drug-Resistant Infections

Vivid Dx (search)Search term, a precision diagnostics company based in Oxford, England, announced on July 28, 2026 that it has raised $15 million in seed financing to advance its direct-from-blood platform designed to rapidly identify dangerous pathogens and guide antibiotic treatment decisions. The financing round was co-led by Oxford Science Enterprises (search)Search term and Cedars-Sinai Intellectual Property Co. (search)Search term, with participation from Jameel Investment Management Company (search)Search term and additional strategic investors. Concurrently, the company appointed scientist and diagnostics executive Keith O'Neill as chief executive officer to steer the company through clinical validation and toward commercialization.

The funding arrives at a time when antimicrobial resistance (search)Search disease (AMR) has emerged as one of the most pressing threats in modern medicine. Researchers estimate that AMR could contribute to 39 million deaths globally between 2025 and 2050. Currently, when a patient presents with a suspected bloodstream infection such as sepsis (search)Search disease, hospitals often wait days for culture-based results to identify the causative pathogen and determine which antibiotics are likely to be effective. During this window, clinicians must treat empirically with broad-spectrum antibiotics — an approach that may fail against drug-resistant organisms and contributes to the further evolution of resistance.

A Platform Built on Raman Spectroscopy and AI

Vivid Dx (search)Search term's platform addresses a longstanding challenge in rapid infectious disease diagnostics: delivering results that are not only fast but also accurate, comprehensive, and practical for clinical workflows. The technology applies artificial intelligence and machine learning (AI/ML) alongside advanced sample preparation to Raman spectroscopy, a validated technique capable of reading biochemical signatures from individual pathogen cells.

The platform integrates three core components: direct-from-blood pathogen isolation, proprietary Raman spectral databases containing thousands of clinical isolates, and AI-powered signal interpretation. Together, these elements are designed to identify pathogens and support phenotypic antimicrobial susceptibility testing (AST) directly from blood samples, with the goal of compressing diagnostic timelines from days to hours.

"For decades, clinicians treating serious infections have had to wait too long for the information needed to guide antibiotic treatment. The biggest delay in today's workflow happens before many diagnostic systems can even begin: clinicians are waiting for culture," said Keith O'Neill, incoming CEO of Vivid Dx (search)Search term. "Our goal is to move those answers closer to the moment a blood sample is taken."

Preclinical Performance and Path to Clinical Validation

To date, Vivid Dx (search)Search term has achieved proof-of-concept across all core platform components, including direct-from-blood pathogen isolation, high-purity bacterial recovery, AI-powered Raman signal enhancement, and the development of its proprietary spectral database. In preclinical testing, the platform demonstrated approximately 99% pathogen identification accuracy and roughly 92% concordance for phenotypic AST testing when compared with gold-standard methods.

The company is now preparing to test its platform with patient-derived clinical samples, a critical step toward demonstrating that the technology can perform reliably in the complex cases hospitals encounter daily. For hospitals, earlier diagnostic insights could enable clinicians to transition from broad-spectrum empiric therapy to targeted treatment sooner, potentially reducing ICU stays, lowering treatment costs, and improving patient outcomes. Faster, more precise treatment decisions could also curtail unnecessary antibiotic exposure, an important factor in slowing the evolution of AMR.

Leadership with Deep Diagnostics Expertise

O'Neill brings to Vivid Dx (search)Search term a career spanning scientific research, diagnostics development, and global healthcare innovation. He worked at MIT on the Human Genome Project, built a multi-institution point-of-care diagnostics program, supported early-stage life sciences companies through Enterprise Ireland, and established global innovation alliances at Abbott. Most recently, he served as CEO of Novus Diagnostics, where he advanced the development of a rapid point-of-care test for bloodstream infections.

"The company has built strong technical foundations, and my focus will be advancing that work through clinical validation and toward a platform that clinicians can adopt routinely to inform patient care decisions," O'Neill said.

Investor Confidence in a Growing Unmet Need

The investment reflects growing recognition that faster diagnostics are essential to both patient care and antibiotic stewardship. "The need for faster infectious disease testing is urgent, but speed alone is not enough — hospitals need results they can trust and integrate into care pathways," said Tony Besse, Principal, Health Tech at Oxford Science Enterprises (search)Search term. "We look forward to supporting Vivid Dx (search)Search term as it takes the next step from technical proof toward the evidence needed for adoption at scale."

Nirdesh Gupta, Managing Director of Cedars-Sinai Technology Ventures at Cedars-Sinai, emphasized the global imperative: "Over the next decade, it's crucial that physicians globally adopt technologies that can help identify pathogens and guide therapy decisions faster and more precisely for drug-resistant infections. We see significant potential in Vivid Dx (search)Search term's approach combining blood-based testing and AI-driven analysis."